CFO
CRL icon

Callan Family Office’s Charles River Laboratories CRL Stock Holding History

Callan Family Office’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$420K Buy
2,435
+16
+0.7% +$2.97K 0.01% 826
2025
Q4 		$483K Buy
2,419
+395
+20% +$71.7K 0.01% 794
2025
Q3 		$317K Sell
2,024
-219
-10% -$34.8K 0.01% 692
2025
Q2 		$340K Buy
+2,243
New +$299K 0.01% 727

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Callan Family Office's CRL Position: Q1 2026 in Review

Callan Family Office increased its Charles River Laboratories (CRL) stake by 0.66% in Q1 2026, buying an estimated $2.97K and bringing the position to 2,435 shares worth $420K. The position accounts for 0.01% of the portfolio, ranked #826.

Callan Family Office first reported a position in CRL in Q2 2025 and has held it in 4 quarters since. The position peaked at $483K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Callan Family Office held 2,435 shares of Charles River Laboratories worth $420K as of Q1 2026.
  • Callan Family Office bought 16 Charles River Laboratories shares in Q1 2026, an estimated $2.97K.
  • Charles River Laboratories made up 0.01% of Callan Family Office's portfolio in Q1 2026, its #826 holding.
  • Callan Family Office first reported a position in Charles River Laboratories in Q2 2025 and has held it in 4 quarters since.
  • Callan Family Office's Charles River Laboratories position peaked at $483K in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.